Freestone Grove Partners LP Makes New $259,000 Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Freestone Grove Partners LP acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,679 shares of the specialty pharmaceutical company's stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in ANIP. Barclays PLC boosted its holdings in ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after buying an additional 135,003 shares in the last quarter. Franklin Resources Inc. grew its position in shares of ANI Pharmaceuticals by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after acquiring an additional 691 shares during the period. JPMorgan Chase & Co. increased its stake in shares of ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in ANI Pharmaceuticals by 67.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after purchasing an additional 125,438 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $544,000. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Up 1.0 %

Shares of ANIP stock traded up $0.71 on Thursday, hitting $71.53. 469,943 shares of the stock traded hands, compared to its average volume of 288,868. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $73.72. The stock has a market capitalization of $1.56 billion, a PE ratio of -130.05 and a beta of 0.56. The firm's 50-day moving average price is $66.45 and its two-hundred day moving average price is $60.55. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares in the company, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $197,792 in the last 90 days. Insiders own 12.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. StockNews.com lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.